Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Sedation before nerve block increases risk, not pain relief

13.02.2014
New research suggests that sedating patients before a nerve block needed to diagnose or treat chronic pain increases costs, risks and unnecessary surgeries, and sedation does nothing to increase patient satisfaction or long-term pain control.

"Sedation doesn't help, but it does add expense and risk," says study leader Steven P. Cohen, M.D., a professor of anesthesiology and critical care medicine at the Johns Hopkins University School of Medicine. "In some places, every patient is being sedated. Our research shows it should be used very sparingly."

Nerve blocks, performed by injecting anesthetics and/or steroids into any number of areas of the body, from the spinal column to the hip joint, are often performed ahead of surgery and in addition to other invasive procedures, such as the ablation of nerves to treat arthritis in the back, to more accurately pin down the source of pain. If the nerve block fails to numb pain, surgery or the nerve ablation may not help. Increasingly, physicians have used light or even deep sedation in a bid to ease anxiety and pain while the injection is given.

However, results of the new study, reported online Feb. 13 in the journal Pain Medicine, show that sedation before a nerve block significantly increases false-positive results, which means patients are more likely to be sent in for surgeries and other procedures that won't cure the underlying pain. Another worry, Cohen says, is the health risk when someone is sedated.

Cohen and researchers from several other medical centers in the United States recruited 73 patients with back or limb pain who were scheduled to receive multiple nerve blocks. Roughly half of the group received the first injection with sedation and the second without. The remaining patients received their injections in the opposite order. Patients were given six-hour pain diaries, a routine step that helps patients determine whether the injections bring relief, and were asked to rate their satisfaction with the treatment. They were also seen a month later and asked to rate their pain and function after the treatment.

Although the sedated patients reported less pain immediately after the nerve block injection, on every other measure — from 30-day pain assessments to overall patient satisfaction — the results were the same whether or not they were sedated.

"A lot of cost for very little benefit," Cohen says.

The increase in false-positive results — the belief that the pain has been relieved when it has not been — can result from many factors, Cohen says. The medication used for the sedation itself can have pain-relieving properties. The sedative can relax muscles. Patients may need to take extra time away from daily activities after being under anesthesia, and that rest alone could make the patient feel better.

But if patients believe that the nerve block eased their underlying pain, the physician will often conclude he or she has found the source and will move ahead with the appropriate treatment, which may include spinal fusion or radiofrequency ablation of nerves for arthritis, Cohen says. In the end, he says, many patients end up back at square one — still in pain, but having suffered through a potentially unnecessary operation.

Cohen says that while many physicians may use sedation in a sincere effort to make the procedure less traumatic for patients, there is also a perverse financial incentive to use it.

"Unfortunately, medicine in many places has become a business. The fact is, you get paid more money to do the procedure with sedation," he says. "The costs of anesthesia can be more than the fee for the procedure itself. And patients are getting harmed."

The research was funded by the Center for Rehabilitation Sciences Research, part of the Uniformed Services University of the Health Sciences in Bethesda, Md.

Haroon Hameed, M.D., and Michael E. Erdek, M.D., both of Johns Hopkins, contributed to this study, as well as researchers from Walter Reed National Military Medical Center in Bethesda; the Uniformed Services University of the Health Sciences; the Mayo Clinic in Scottsdale, Ariz.; the Cleveland Clinic in Ohio; and the University of Florida in Gainesville.

Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $6.7 billion integrated global health enterprise and one of the leading health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. JHM's vision, "Together, we will deliver the promise of medicine," is supported by its mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, JHM educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness. JHM operates six academic and community hospitals, four suburban health care and surgery centers, and more than 30 primary health care outpatient sites. The Johns Hopkins Hospital, opened in 1889, was ranked number one in the nation for 21 years in a row by U.S. News & World Report.

Media Contacts:
Stephanie Desmon; 410-955-8665; sdesmon1@jhmi.edu
Lauren Nelson; 410-955-8725; lnelso35@jhmi.edu

Stephanie Desmon | EurekAlert!
Further information:
http://www.jhmi.edu

More articles from Health and Medicine:

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

nachricht How to turn white fat brown
07.12.2016 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>